Evolus, Inc. (NASDAQ:EOLS) CFO Sells $30,826.60 in Stock

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 3,178 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $9.70, for a total transaction of $30,826.60. Following the completion of the sale, the chief financial officer now owns 113,368 shares in the company, valued at approximately $1,099,669.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Evolus Stock Down 2.9 %

NASDAQ EOLS opened at $9.52 on Monday. The company has a current ratio of 2.33, a quick ratio of 1.85 and a debt-to-equity ratio of 10.37. The stock’s 50 day moving average is $8.88 and its two-hundred day moving average is $8.71. The company has a market capitalization of $542.35 million, a price-to-earnings ratio of -8.14 and a beta of 1.60. Evolus, Inc. has a 1-year low of $6.51 and a 1-year high of $11.49.

Evolus (NASDAQ:EOLS) last issued its earnings results on Wednesday, August 2nd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). Evolus had a negative net margin of 39.36% and a negative return on equity of 507.42%. The firm had revenue of $49.35 million during the quarter, compared to analyst estimates of $46.12 million. Equities analysts forecast that Evolus, Inc. will post -0.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on EOLS. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Evolus in a research report on Thursday, August 3rd. Truist Financial lifted their target price on Evolus from $14.00 to $18.00 in a research report on Friday, May 26th. Mizuho lifted their price target on shares of Evolus from $17.00 to $20.00 in a research note on Wednesday, June 7th. Finally, HC Wainwright lifted their price target on shares of Evolus from $16.00 to $27.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd.

Institutional Investors Weigh In On Evolus

Several institutional investors and hedge funds have recently made changes to their positions in the company. California State Teachers Retirement System boosted its stake in shares of Evolus by 12.6% in the 2nd quarter. California State Teachers Retirement System now owns 50,990 shares of the company’s stock valued at $371,000 after purchasing an additional 5,706 shares in the last quarter. Legato Capital Management LLC boosted its holdings in shares of Evolus by 36.0% in the 2nd quarter. Legato Capital Management LLC now owns 102,787 shares of the company’s stock worth $747,000 after acquiring an additional 27,208 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in shares of Evolus by 25.4% in the 2nd quarter. Alliancebernstein L.P. now owns 64,960 shares of the company’s stock worth $472,000 after acquiring an additional 13,160 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Evolus by 406.5% in the 2nd quarter. Wells Fargo & Company MN now owns 58,259 shares of the company’s stock worth $424,000 after acquiring an additional 46,757 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Evolus by 25.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 170,631 shares of the company’s stock worth $1,240,000 after acquiring an additional 34,632 shares in the last quarter. Institutional investors and hedge funds own 65.15% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.